Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase NA 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × erdafitinib × Clear all
NCT03732703 2025-02-14

MyDRUG

Multiple Myeloma Research Consortium

Phase 1/2 Completed
103 enrolled
Plasma cell

Multiple Myeloma

NCT02421185 2025-02-03

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Janssen Research & Development, LLC

Phase 1/2 Completed
53 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡